Athira Pharma has begun dosing patients in its Phase 2 clinical trial evaluating ATH-1017, an investigational small molecule for the treatment of mild to moderate Alzheimer’s disease. Clinical efficacy will be demonstrated by improvements in cognition and functional assessments among participants, compared with a placebo. “The initiation of our second late-stage study for ATH-1017 represents a significant milestone for Athira as we advance our clinical program to treat this area of immense medical need,” Hans…
You must be logged in to read/download the full post.
The post Dosing Starts in Athira’s Phase 2 ACT-AD Trial Testing ATH-1017; Enrollment Ongoing appeared first on BioNewsFeeds.